万古霉素单药治疗可能不足以应对流感相关危重症儿童的耐甲氧西林金黄色葡萄球菌合并感染
该研究纳入34个儿童重症监护室中2008年11月至2016年5月间因流感感染和呼吸衰竭住院的170名儿童,比较MRSA合并感染、非MRSA细菌合并感染和无细菌合并感染三组。流感-MRSA合并感染患儿死亡率40%,无MRSA合并感染为4.3%(RR 9.3,95%CI 3.8-22.9)。在24小时内接受万古霉素的29名MRSA患儿中,加用第二种抗MRSA抗生素者死亡率为12.5%(2/16),单用万古霉素者为69.2%(9/13)(RR 5.5,95%CI 1.4-21.3,P=.003)。
要点
- 流感-MRSA合并感染患儿死亡率40%,显著高于无MRSA合并感染者的4.3%。
- 万古霉素单药治疗者死亡率69.2%,加用第二种抗MRSA抗生素者12.5%。
- 78%的万古霉素初始谷浓度<10 µg/mL,万古霉素剂量不影响初始谷浓度。
核心结论
- 流感-MRSA合并感染与危重患儿高死亡率相关。
- 数据支持在疑似重症病例中早期加用第二种抗MRSA抗生素与万古霉素联合使用。
研究设计与样本
- 多中心队列研究,纳入34个儿童重症监护室中2008年11月至2016年5月间年龄<18岁、流感感染且呼吸衰竭的儿童170例(甲型流感127例,乙型流感43例)。
- 比较MRSA合并感染(N=30)、非MRSA细菌合并感染(N=61)和无细菌合并感染(N=79)三组患儿的基线特征、临床病程和治疗。
主要发现
- 流感-MRSA肺炎患儿(N=30,87%既往健康)年龄大于非MRSA合并感染(N=61)或无细菌合并感染(N=79)患儿。
- 流感-MRSA合并感染与白细胞减少、急性肺损伤、血管升压药使用、体外生命支持和死亡率增加相关(P≤.0001)。
- 流感相关死亡率MRSA合并感染为40%,无MRSA合并感染为4.3%(相对危险度[RR] 9.3;95%置信区间[CI] 3.8-22.9)。
- 在29/30名住院24小时内接受万古霉素的MRSA患儿中,加用第二种抗MRSA抗生素者死亡率为12.5%(N=2/16),单用万古霉素者为69.2%(N=9/13)(RR 5.5;95%CI 1.4-21.3;P=.003)。
- 万古霉素剂量不影响初始谷浓度;78%的初始谷浓度<10 µg/mL。
临床怎么用
- 作者认为数据支持在疑似重症流感-MRSA合并感染病例中早期加用第二种抗MRSA抗生素与万古霉素联合使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coinfection with influenza virus and methicillin-resistant Staphylococcus aureus (MRSA) causes life-threatening necrotizing pneumonia in children. Sporadic incidence precludes evaluation of antimicrobial efficacy. We assessed the clinical characteristics and outcomes of critically ill children with influenza-MRSA pneumonia and evaluated antibiotic use. METHODS: We enrolled children (<18 years) with influenza infection and respiratory failure across 34 pediatric intensive care units 11/2008-5/2016. We compared baseline characteristics, clinical courses, and therapies in children with MRSA coinfection, non-MRSA bacterial coinfection, and no bacterial coinfection. RESULTS: We enrolled 170 children (127 influenza A, 43 influenza B). Children with influenza-MRSA pneumonia (N = 30, 87% previously healthy) were older than those with non-MRSA (N = 61) or no (N = 79) bacterial coinfections. Influenza-MRSA was associated with increased leukopenia, acute lung injury, vasopressor use, extracorporeal life support, and mortality than either group (P ≤ .0001). Influenza-related mortality was 40% with MRSA compared to 4.3% without (relative risk [RR], 9.3; 95% confidence interval [CI], 3.8-22.9). Of 29/30 children with MRSA who received vancomycin within the first 24 hours of hospitalization, mortality was 12.5% (N = 2/16) if treatment also included a second anti-MRSA antibiotic compared to 69.2% (N = 9/13) with vancomycin monotherapy (RR, 5.5; 95% CI, 1.4, 21.3; P = .003). Vancomycin dosing did not influence initial trough levels; 78% were <10 µg/mL. CONCLUSIONS: Influenza-MRSA coinfection is associated with high fatality in critically ill children. These data support early addition of a second anti-MRSA antibiotic to vancomycin in suspected severe cases.
引用
- Randolph AG, Xu R, Novak T, et al. Vancomycin Monotherapy May Be Insufficient to Treat Methicillin-resistant Staphylococcus aureus Coinfection in Children With Influenza-related Critical Illness. Clin Infect Dis. 2019. PMID: 29893805. doi:10.1093/cid/ciy495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。